DelveInsight’s “Androgenic Alopecia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Androgenic Alopecia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Androgenic Alopecia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Androgenic Alopecia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Androgenic Alopecia: An Overview
Androgenetic Alopecia (AGA) or hair loss, is often referred to as ‘Male Pattern Baldness’ or ‘Female Pattern Baldness’. Hair loss is a matter of enormous public interest and it significantly impacts the patient’s mental health. In-depth insights into the pathophysiology and treatment landscape of various types of alopecia are imperative to exert a positive influence on the quality of life of the patients.
Androgenic Alopecia is caused by a combination of genetic and hormonal factors. Dihydrotestosterone (DHT) is the main hormone responsible for AGA in genetically susceptible individuals. DHT causes scalp hair loss by inducing a change in the hair follicles on the scalp. The diagnosis is based on the evaluation of underlying medical history and is usually done as a three-stage physical examination of the scalp, follicular unit, and density. The pull technique is also used to clinically assess Androgenic Alopecia.
The current treatment landscape has only minoxidil and finasteride, which are FDA-approved. There are other off-label therapies such as Ketaconazole and Spironolactone that govern the prescription pattern. This pattern is likely to change post-launch of potential pipeline products (Clascoterone, FOL-005) in the next decade.
Androgenic Alopecia Market Key Facts
-
In the 7MM, the Androgenic Alopecia market size was approximately USD 5,600 million in 2021.
-
The total prevalent cases of Androgenic Alopecia were more than 194,000,000 in the 7MM in 2021.
-
As per the estimates, EU4 and the UK had the highest prevalent patient population of androgenetic alopecia in 2021. Among EU4 and the UK, Germany had the highest number of cases of androgenetic alopecia, with more than 22,000,000 cases, followed by the UK in 2021. On the other hand, Spain had the lowest number of cases of androgenetic alopecia, with nearly 12,000,000 cases in 2021.
-
As per the study by Severi et al., the prevalence of vertex and full Androgenic Alopecia increased with age from approximately 30% (age 40–55 years) to 50% (age 65–69 years).
-
Rhodes et al. specified that the prevalence of moderate or severe male Androgenic Alopecia was approximately 50% in the age group 40–49.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Androgenic Alopecia pipeline therapies. It also thoroughly assesses the Androgenic Alopecia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Androgenic Alopecia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Androgenic Alopecia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Androgenic Alopecia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Androgenic Alopecia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Androgenic Alopecia Epidemiology, Segmented as –
-
Prevalent cases of Androgenetic Alopecia in the 7MM [2019–2032]
-
Diagnosed and Treatable cases of Androgenetic Alopecia in the 7MM [2019–2032]
-
Age-specific Prevalence of Androgenetic Alopecia in the 7MM [2019–2032]
-
Gender-specific Prevalence of Androgenetic Alopecia in the 7MM [2019–2032]
-
Risk Factor Prevalent cases of Androgenetic Alopecia in 7MM [2019–2032]
Androgenic Alopecia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Androgenic Alopecia market or expected to be launched during the study period. The analysis covers the Androgenic Alopecia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Androgenic Alopecia drugs based on their sale and market share.
The report also covers the Androgenic Alopecia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Androgenic Alopecia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Androgenic Alopecia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/androgenetic-alopecia-market
Androgenic Alopecia Therapeutics Analysis
Presently, there is no cure available for Androgenic Alopecia. The choice of treatment for AGA depends on various factors, including efficacy, practicability, risks, and costs. The aim is to prevent the miniaturization process and, if possible, to reverse it. Treatments include pharmacotherapy, surgery, and cosmetic aids.
Androgenic Alopecia is the result of a genetic predisposition; however, evidence shows that the cause is androgen-related. DHT is the primary androgen involved in Androgenic Alopecia, with DHT concentrations being higher in men with Androgenic Alopecia. Circulating testosterone is converted to DHT by 5AR. There are three types of alpha-reductase receptor isoenzymes, and type I and type II are significant in the treatment of AGA.
Type I is located in the skin, including the sebaceous glands and hair follicles, and type II is located in the inner root sheath of hair follicles in the scalp, face, chest, genitals, and prostate gland. The hair-growth cycle is also affected in Androgenic Alopecia. Hair in the telogen, or dormant, phase is more predominant than hair in the anagen, or growth, stage. This leads to a decrease in hair on certain areas of the head. In addition, some of the hair follicles are smaller and more sensitive to androgen. The pattern in which the hair loss occurs is genetically predetermined by the distribution of these smaller hair follicles
To advance the treatment landscape for Androgenetic Alopecia, several major pharma and biotech companies are actively engaged in developing therapies. Notably, Kintor Pharma is a prominent player, with Androgenetic Alopecia drug candidates progressing to the most advanced stage, Phase II clinical trials.
Androgenic Alopecia Companies Actively Working in the Therapeutics Market Include
Kerastem, Addpharma, Cutia Therapeutics, Biosplice Therapeutics, Aclaris Therapeutics, Kintor Pharmaceutical, Dong-AST Co., Ltd., Cassiopea, Follica, Applied Biology, Inc., AndroScience Corporation, AnnJi Pharmaceutical, Carmell Therapeutics, and many others.
Emerging and Marketed Androgenic Alopecia Therapies Covered in the Report Include:
-
BREEZULA: Cosmo Pharmaceuticals
-
KX-826: Kintor Pharmaceutical
-
XEOMIN: Merz Aesthetics
-
KX-826: Kintor Pharma
-
Clascoterone: Cassiopea
-
FOL-005: Follicum AB
-
Clascoterone solution 7.5%: Cassiopea, Inc.
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/androgenetic-alopecia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Androgenic Alopecia Competitive Intelligence Analysis
4. Androgenic Alopecia Market Overview at a Glance
5. Androgenic Alopecia Disease Background and Overview
6. Androgenic Alopecia Patient Journey
7. Androgenic Alopecia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Androgenic Alopecia Treatment Algorithm, Current Treatment, and Medical Practices
9. Androgenic Alopecia Unmet Needs
10. Key Endpoints of Androgenic Alopecia Treatment
11. Androgenic Alopecia Marketed Therapies
12. Androgenic Alopecia Emerging Drugs and Latest Therapeutic Advances
13. Androgenic Alopecia Seven Major Market Analysis
14. Attribute Analysis
15. Androgenic Alopecia Market Outlook (In US, EU5, and Japan)
16. Androgenic Alopecia Companies Active in the Market
17. Androgenic Alopecia Access and Reimbursement Overview
18. KOL Views on the Androgenic Alopecia Market
19. Androgenic Alopecia Market Drivers
20. Androgenic Alopecia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/androgenetic-alopecia-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Hepatic Impairment Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hepatic Impairment market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hepatic Impairment market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research